Nature Communications (Mar 2017)
Long-acting protein drugs for the treatment of ocular diseases
- Joy G. Ghosh,
- Andrew A. Nguyen,
- Chad E. Bigelow,
- Stephen Poor,
- Yubin Qiu,
- Nalini Rangaswamy,
- Richard Ornberg,
- Brittany Jackson,
- Howard Mak,
- Tucker Ezell,
- Vania Kenanova,
- Elisa de la Cruz,
- Ana Carrion,
- Bijan Etemad-Gilbertson,
- Roxana Garcia Caro,
- Kan Zhu,
- Vinney George,
- Jirong Bai,
- Radhika Sharma-Nahar,
- Siyuan Shen,
- Yiqin Wang,
- Kulandayan K. Subramanian,
- Elizabeth Fassbender,
- Michael Maker,
- Shawn Hanks,
- Joanna Vrouvlianis,
- Barrett Leehy,
- Debby Long,
- Melissa Prentiss,
- Viral Kansara,
- Bruce Jaffee,
- Thaddeus P. Dryja,
- Michael Roguska
Affiliations
- Joy G. Ghosh
- Novartis Institutes for BioMedical Research
- Andrew A. Nguyen
- Novartis Institutes for BioMedical Research
- Chad E. Bigelow
- Novartis Institutes for BioMedical Research
- Stephen Poor
- Novartis Institutes for BioMedical Research
- Yubin Qiu
- Novartis Institutes for BioMedical Research
- Nalini Rangaswamy
- Novartis Institutes for BioMedical Research
- Richard Ornberg
- Novartis Institutes for BioMedical Research
- Brittany Jackson
- Novartis Institutes for BioMedical Research
- Howard Mak
- Novartis Institutes for BioMedical Research
- Tucker Ezell
- Novartis Institutes for BioMedical Research
- Vania Kenanova
- Novartis Institutes for BioMedical Research
- Elisa de la Cruz
- Novartis Institutes for BioMedical Research
- Ana Carrion
- Novartis Institutes for BioMedical Research
- Bijan Etemad-Gilbertson
- Novartis Institutes for BioMedical Research
- Roxana Garcia Caro
- Novartis Institutes for BioMedical Research
- Kan Zhu
- Novartis Institutes for BioMedical Research
- Vinney George
- Novartis Institutes for BioMedical Research
- Jirong Bai
- Novartis Institutes for BioMedical Research
- Radhika Sharma-Nahar
- Novartis Institutes for BioMedical Research
- Siyuan Shen
- Novartis Institutes for BioMedical Research
- Yiqin Wang
- Novartis Institutes for BioMedical Research
- Kulandayan K. Subramanian
- Novartis Institutes for BioMedical Research
- Elizabeth Fassbender
- Novartis Institutes for BioMedical Research
- Michael Maker
- Novartis Institutes for BioMedical Research
- Shawn Hanks
- Novartis Institutes for BioMedical Research
- Joanna Vrouvlianis
- Novartis Institutes for BioMedical Research
- Barrett Leehy
- Novartis Institutes for BioMedical Research
- Debby Long
- Novartis Institutes for BioMedical Research
- Melissa Prentiss
- Novartis Institutes for BioMedical Research
- Viral Kansara
- Novartis Institutes for BioMedical Research
- Bruce Jaffee
- Novartis Institutes for BioMedical Research
- Thaddeus P. Dryja
- Novartis Institutes for BioMedical Research
- Michael Roguska
- Novartis Institutes for BioMedical Research
- DOI
- https://doi.org/10.1038/ncomms14837
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 10
Abstract
Retinal vascular disease treatments involve frequent pharmacological intraocular administrations. Here the authors present a method to increase the half-life of injected drugs by fusing these to a hyaluronan-binding peptide, which might lead to less frequent retinal disease treatments.
